• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

提高造血细胞移植后疫苗复种及时性和依从性的质量改进措施:在移植项目中实施疫苗复种门诊。

Quality Improvement Initiative to Improve Time and Adherence to Revaccination after Hematopoietic Cell Transplantation: Implementation of a Revaccination Clinic within the Transplantation Program.

机构信息

Cellular Therapy and Transplantation Section, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Cellular Therapy and Transplantation Section, Division of Oncology, Children's Hospital of Philadelphia, Philadelphia.

出版信息

Transplant Cell Ther. 2023 Oct;29(10):635.e1-635.e8. doi: 10.1016/j.jtct.2023.07.020. Epub 2023 Jul 28.

DOI:10.1016/j.jtct.2023.07.020
PMID:37517611
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10592250/
Abstract

Revaccination after hematopoietic cell transplantation (HCT) is critical to prevent morbidity and mortality from vaccine-preventable illnesses. The global aim of our quality improvement initiative was to enhance timely, correct, and effective revaccination after pediatric HCT. The SMART aim of our project was to decrease median unvaccinated time by 4 months by decreasing the time to vaccine eligibility, time from eligibility to vaccine initiation, and time to completion of the vaccine series. A multidisciplinary group performed a cross-sectional quantitative and qualitative evaluation of revaccination practices at our institution. We identified factors associated with delayed, incorrect, or incomplete revaccination. Several plan-do-study-act interventions were implemented to address these drivers, including revising immune readiness criteria, increasing auditing of primary care administered immunizations, and, importantly, establishing a dedicated revaccination clinic within the HCT clinic at our center. The time to vaccine eligibility decreased from 12.6 months to 10 months (a 20% decrease), and the time to complete the vaccine series decreased from 19.3 months to 15.7 months (a 19% decrease). With a quality improvement initiative, we addressed the many causes of delayed or incomplete revaccination post-HCT and through a team-based approach successfully decreased the time to vaccine start and time to vaccine completion at our center.

摘要

造血细胞移植(HCT)后再接种疫苗对于预防疫苗可预防疾病的发病率和死亡率至关重要。我们质量改进计划的全球目标是加强儿科 HCT 后及时、正确和有效地进行再接种。我们项目的 SMART 目标是通过减少疫苗接种资格时间、从资格到疫苗接种开始时间以及完成疫苗系列的时间,将中位数未接种时间减少 4 个月。一个多学科小组对我们机构的再接种实践进行了横断面定量和定性评估。我们确定了与延迟、不正确或不完整再接种相关的因素。实施了几项计划-执行-研究-行动干预措施来解决这些驱动因素,包括修订免疫准备标准、增加对初级保健管理的免疫接种的审核,以及在我们中心的 HCT 诊所内建立专门的再接种诊所。疫苗接种资格时间从 12.6 个月减少到 10 个月(减少 20%),完成疫苗系列的时间从 19.3 个月减少到 15.7 个月(减少 19%)。通过质量改进计划,我们解决了 HCT 后延迟或不完全再接种的许多原因,并通过基于团队的方法成功地减少了我们中心的疫苗开始时间和疫苗完成时间。

相似文献

1
Quality Improvement Initiative to Improve Time and Adherence to Revaccination after Hematopoietic Cell Transplantation: Implementation of a Revaccination Clinic within the Transplantation Program.提高造血细胞移植后疫苗复种及时性和依从性的质量改进措施:在移植项目中实施疫苗复种门诊。
Transplant Cell Ther. 2023 Oct;29(10):635.e1-635.e8. doi: 10.1016/j.jtct.2023.07.020. Epub 2023 Jul 28.
2
Revaccination following CAR-T therapy: a needs assessment.嵌合抗原受体T细胞(CAR-T)疗法后的再次接种疫苗:需求评估
Hematology. 2025 Dec;30(1):2519865. doi: 10.1080/16078454.2025.2519865. Epub 2025 Jun 23.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Effectiveness, immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly: a systematic review.23价肺炎球菌多糖疫苗再次接种在老年人中的有效性、免疫原性及安全性:一项系统评价
BMC Infect Dis. 2016 Nov 25;16(1):711. doi: 10.1186/s12879-016-2040-y.
5
Integrated management of childhood illness (IMCI) strategy for children under five.五岁以下儿童疾病综合管理(IMCI)策略
Cochrane Database Syst Rev. 2016 Jun 22;2016(6):CD010123. doi: 10.1002/14651858.CD010123.pub2.
6
Interventions for improving adherence to amblyopia treatments in children.改善儿童弱视治疗依从性的干预措施。
Cochrane Database Syst Rev. 2025 Jul 2;7(7):CD015820. doi: 10.1002/14651858.CD015820.pub2.
7
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.社区居住的老年人跌倒预防干预措施:系统评价和荟萃分析的益处、危害以及患者的价值观和偏好。
Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3.
8
Rehabilitation following surgery for lumbar spinal stenosis.腰椎管狭窄症手术后的康复
Cochrane Database Syst Rev. 2013 Dec 9;2013(12):CD009644. doi: 10.1002/14651858.CD009644.pub2.
9
Factors that influence parents' and informal caregivers' views and practices regarding routine childhood vaccination: a qualitative evidence synthesis.影响父母和非正式照顾者对常规儿童疫苗接种看法和做法的因素:定性证据综合分析。
Cochrane Database Syst Rev. 2021 Oct 27;10(10):CD013265. doi: 10.1002/14651858.CD013265.pub2.
10
Improving Health Care Transition for Young Patients With Sickle Cell Disease Through Quality Network.通过质量网络改善镰状细胞病年轻患者的医疗保健过渡
JAMA Netw Open. 2025 Apr 1;8(4):e254957. doi: 10.1001/jamanetworkopen.2025.4957.

引用本文的文献

1
Supportive Care in Pediatric Oncology: Opportunities and Future Directions.儿科肿瘤学中的支持性护理:机遇与未来方向。
Cancers (Basel). 2023 Nov 23;15(23):5549. doi: 10.3390/cancers15235549.

本文引用的文献

1
A Retrospective Review of Revaccination Patterns in Pediatric Hematopoietic Stem Cell Transplantation Recipients.儿科造血干细胞移植受者再接种模式的回顾性研究
J Pediatr Hematol Oncol Nurs. 2023 Jul-Aug;40(4):259-264. doi: 10.1177/27527530221147861. Epub 2023 Apr 17.
2
Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients: Prepared on behalf of the British society of blood and marrow transplantation and cellular therapy (BSBMTCT), the Children's cancer and Leukaemia Group (CCLG), and British Infection Association (BIA).成人及儿童造血干细胞移植受者疫苗接种联合共识声明:由英国血液与骨髓移植及细胞治疗学会(BSBMTCT)、儿童癌症与白血病研究组(CCLG)以及英国感染协会(BIA)联合制定。
J Infect. 2023 Jan;86(1):1-8. doi: 10.1016/j.jinf.2022.11.005. Epub 2022 Nov 15.
3
Vaccine Adherence and Postvaccination Serological Status of Pediatric Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Single-center Experience.儿科异基因造血干细胞移植受者的疫苗依从性和疫苗接种后血清学状态:单中心经验。
J Pediatr Hematol Oncol. 2023 Apr 1;45(3):e370-e377. doi: 10.1097/MPH.0000000000002535. Epub 2022 Aug 30.
4
A Population-Based Study of the Long-Term Risk of Infections Associated With Hospitalization in Childhood Cancer Survivors.基于人群的研究:儿童癌症幸存者住院相关感染的长期风险。
J Clin Oncol. 2023 Jan 10;41(2):364-372. doi: 10.1200/JCO.22.00230. Epub 2022 Jul 25.
5
Vaccine Responses in Adult Hematopoietic Stem Cell Transplant Recipients: A Comprehensive Review.成人造血干细胞移植受者的疫苗反应:一项综述
Cancers (Basel). 2021 Dec 6;13(23):6140. doi: 10.3390/cancers13236140.
6
Long-term survivors following autologous haematopoetic stem cell transplantation have significant defects in their humoral immunity against vaccine preventable diseases, years on from transplant.自体造血干细胞移植后长期存活的患者,在移植多年后,其针对可通过疫苗预防的疾病的体液免疫存在显著缺陷。
Vaccine. 2021 Aug 9;39(34):4778-4783. doi: 10.1016/j.vaccine.2021.07.022. Epub 2021 Jul 20.
7
Primary vaccination in adult patients after allogeneic hematopoietic stem cell transplantation - A single center retrospective efficacy analysis.异基因造血干细胞移植后成年患者的初次疫苗接种 - 一项单中心回顾性疗效分析。
Vaccine. 2021 Jul 30;39(33):4742-4750. doi: 10.1016/j.vaccine.2021.04.052. Epub 2021 May 25.
8
An Immune Recovery-Based Revaccination Protocol for Pediatric Hematopoietic Stem Cell Transplant Recipients: Revaccination Outcomes Following Pediatric HSCT.基于免疫恢复的儿科造血干细胞移植受者再接种方案:儿科 HSCT 后的再接种结果。
Transplant Cell Ther. 2021 Apr;27(4):317-326. doi: 10.1016/j.jtct.2021.01.017. Epub 2021 Jan 28.
9
Severe infections following treatment for childhood cancer: a report from CYP-C.儿童癌症治疗后的严重感染:来自 CYP-C 的报告。
Leuk Lymphoma. 2020 Dec;61(12):2876-2884. doi: 10.1080/10428194.2020.1789626. Epub 2020 Jul 12.
10
Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient.造血干细胞移植受者和血液恶性肿瘤患者的疫苗接种。
Infect Dis Clin North Am. 2019 Jun;33(2):593-609. doi: 10.1016/j.idc.2019.02.007.